

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NI, et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: Human Endometrial Specific Steroid-
Binding Factor I, II and III

Atty. Docket No.: PF257D3

**PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.121
AND STATEMENTS UNDER 37 C.F.R. § 1.825(a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examining the captioned application, Applicants respectfully request the entry of the following amendment. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet together with the appropriate fee; (b) a Version With Markings to Show Changes Made; (c) an Information Disclosure Statement and revised Form PTO/SB/08; and (d) Submission of Formal Drawings and accompanying six (6) sheets of Formal Drawings depicting Figures 1-9. Please amend the application as follows.

In the Specification:

Page 1, immediately after the title, please insert following new paragraph:

-- This application is a divisional and claims priority under 35 U.S.C. § 120 to Application Serial No. 09/583,169, filed May 30, 2000, which is a divisional of Application Serial No. 09/263,810, filed March 8, 1999 (now issued Patent No. US 6,174,992 B1), which is a divisional of Application Serial No. 08/821,451, filed March 21,

1997 (now issued Patent No. 6,066,724), which claims priority under 35 U.S.C. § 119(e) to Provisional Application Serial No. 60/014,724, filed March 21, 1996, all herein incorporated by reference in their entirety. --

Page 24, please replace the paragraph beginning on line 1 with the following paragraph:

--The deposited clone was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA, on January 2, 1996 and assigned ATCC Deposit No. 97401, 97402 and 97403.--

Sequence Listing

Please delete the original Sequence Listing (at pages 66-76) and replace it with the Substitute Sequence Listing (pages 1-11) submitted herewith. Please renumber the claims and abstract (pages 77-82) of the specification as pages 66-71.

In the Drawings

Please replace the informal drawings of Figures 1-9 with the formal drawings of Figures 1-9 accompanying the application filed concurrently herewith.

Statements Under 37 C.F.R. § 1.825(a) and (b)

Applicants herewith submit a paper copy of a Substitute Sequence Listing (11 pages) and, a computer-readable diskette containing the Substitute Sequence Listing. The Substitute Sequence Listing (paper copy and computer readable form (CRF)) is submitted herewith to comply with current format requirements under 37 C.F.R. § 1.823 and § 1.824.

As such, in accordance with 37 C.F.R. § 1.825(a), the undersigned attorney for Applicants hereby states that sequence information contained in the Substitute Sequence Listing submitted herewith is identical to the sequence information contained in the Sequence Listing of the specification as originally filed. Therefore, the Substitute Sequence listing is completely supported by the specification as originally filed, and no new matter has been introduced.

In accordance with 37 C.F.R. § 1.825(b), the undersigned attorney for Applicants hereby states that the information in the paper copy of the Substitute Sequence Listing submitted herewith is identical to the information contained in the computer readable form of the Substitute Sequence Listing submitted herewith.

REMARKS


The specification has been amended to claim benefit of priority of the related applications, to update the address of the ATCC, to enter the Substitute Sequence Listing, and to renumber the pages of the claims and abstract in conformance with PTO rules. The drawings have been amended to replace informal drawings of Figures 1-9 with formal drawings of Figures 1-9 of the instant application.

No new matter has been added by these amendments.

Applicants believe that no fee is required for this submission. However, if a fee is required, please charge Deposit Account No. 08-3425 for the appropriate amount.

Respectfully submitted,

Dated: November 6, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosures
JLK/DS/lcc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NI et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: HEREWITH

Examiner: To be assigned

For: Human Endometrial Specific
Steroid-Binding Factor I, II, and III

Attorney Docket No.: PF257D3

Version With Markings To Show Changes Made

In the Specification:

Page 24, the paragraph beginning on line 1 has been amended as follows:

The deposited clone was deposited with the American Type Culture Collection,
[12301 Parklawn Drive, Rockville, Maryland 20852] 10801 University Boulevard,
Manassas, VA 20110-2209, USA, on January 2, 1996 and assigned ATCC Deposit
No. 97401, 97402 and 97403.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NI, et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: Human Endometrial Specific Steroid-
Binding Factor I, II and III

Atty. Docket No.: PF257D3

SUBMISSION OF FORMAL DRAWINGS

Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicants submit herewith Formal Drawings of Figures 1-9 (six sheets) to
replace the originally filed informal drawings of Figures 1-9 (nine sheets).

No fee is believed due for this submission. In the event that a fee is required
in connection with this submission, please charge the required fee to Deposit Account
No. 08-3425.

Respectfully submitted,

Dated: November 6, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 251-6015

Enclosures
JLK/DAS/lcc